208 reports of this reaction
1.4% of all EMICIZUMAB reports
#13 most reported adverse reaction
JOINT INJURY is the #13 most commonly reported adverse reaction for EMICIZUMAB, manufactured by Genentech, Inc.. There are 208 FDA adverse event reports linking EMICIZUMAB to JOINT INJURY. This represents approximately 1.4% of all 15,224 adverse event reports for this drug.
Patients taking EMICIZUMAB who experience joint injury should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
JOINT INJURY is a less commonly reported adverse event for EMICIZUMAB, but still significant enough to appear in the safety profile.
In addition to joint injury, the following adverse reactions have been reported for EMICIZUMAB:
The following drugs have also been linked to joint injury in FDA adverse event reports:
JOINT INJURY has been reported as an adverse event in 208 FDA reports for EMICIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
JOINT INJURY accounts for approximately 1.4% of all adverse event reports for EMICIZUMAB, making it a notable side effect.
If you experience joint injury while taking EMICIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.